Should romosozumab be used in patients with a history or risk of CVD?

Romosozumab offers substantial fracture protection, but its use in patients with cardiovascular disease or risk factors for cardiovascular disease remains uncertain. Randomized trials have yielded conflicting cardiovascular findings, and meta-analyses have not definitively excluded clinically relevant harm. Observational studies generally report no increased risk compared with other osteoporosis treatments, including in some patients with previous cardiovascular events. However, these findings are limited by treatment-selection bias, heterogeneous outcome definitions, and relatively short follow-up. Thus, in patients with established cardiovascular disease, a potential risk remains biologically plausible but unproven. Careful patient selection is still required, and individuals with established cardiovascular disease should be excluded based on US and European labeling advice. More studies are still needed to understand the basic biology of sclerostin relative to atherosclerosis and vessel calcification.

Authors

Institutions

Publication Details

Journal
European Journal of Endocrinology
Published
2026-11-12
DOI
https://doi.org/10.1093/ejendo/lvag202
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Should romosozumab be used in patients with a history or risk of CVD?

Clifford james Rosen, Linyi Liu, Hanghang Liu
1 links
European Journal of Endocrinology
Bone health and osteoporosis research
article

Should romosozumab be used in patients with a history or risk of CVD?

Clifford james Rosen, Linyi Liu, Hanghang Liu
article en

Abstract

Romosozumab offers substantial fracture protection, but its use in patients with cardiovascular disease or risk factors for cardiovascular disease remains uncertain. Randomized trials have yielded conflicting cardiovascular findings, and meta-analyses have not definitively excluded clinically relevant harm. Observational studies generally report no increased risk compared with other osteoporosis treatments, including in some patients with previous cardiovascular events. However, these findings are limited by treatment-selection bias, heterogeneous outcome definitions, and relatively short follow-up. Thus, in patients with established cardiovascular disease, a potential risk remains biologically plausible but unproven. Careful patient selection is still required, and individuals with established cardiovascular disease should be excluded based on US and European labeling advice. More studies are still needed to understand the basic biology of sclerostin relative to atherosclerosis and vessel calcification.

European Journal of Endocrinology
Sichuan University (CN), MaineHealth (US)
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon